CDC Logo Tuberculosis Information CD-ROM   Image of people
     
jump over main navigation bar to content area
Home
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Newsletters
Ordering Information
Help

 

U.S. Department of Health and Human Services

  

Core Curriculum on Tuberculosis, 2000

Chapter 7
Treatment of TB Disease

Selected Bibliography

Abbott Laboratories. Norvir package insert. Chicago, Illinois: Abbott Laboratories, 1999.

Benedek IH, Joshi A, Fiske WD, et al. Pharmacokinetic interaction between efavirenz and rifampin in healthy volunteers [Abstract]. In: Program and abstracts of the 12th World AIDS Conference, Geneva, Switzerland, 1998.

Bloch AB, Simone PM, McCray E, Castro KG. Preventing multidrug-resistant tuberculosis (editorial). JAMA 1996;275(6):487-489.

Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995;155:1595-1600.

Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996;154:1034-1038.

Chaulk CP and Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis. JAMA 1998;279:943-948.

Davidson PT. Managing tuberculosis during pregnancy. Lancet 1995;346:199-200.

Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a clinical reappraisal of the literature. Clin Infect Dis 1997;25:872-887.

Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis -- we canít afford not to try it. N Engl J Med 1993;328(8):576-578.

Iseman MD, Sbarbaro JA. Short-course chemotherapy of tuberculosis: Hail Britannia (and friends)! Am Rev Respir Dis 1991;143:697-698.

Jones BE, Otaya M, Antoniskis D, et al. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1994;150:1499-1502.

Kassim S, Sassan-Morokro M, Ackah A, et al. Two-year follow up of persons with HIV-1 - and HIV-2 - associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995;9:1185-1191.

Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA 1993;270(1):65-68.

Mitchison DA. Drug resistance in mycobacteria. British Med Bull 1984;40:84-90.

Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998;2:10-15.

Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997;102:164-170.

Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997;18:79-87.

Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996;30:919-925.

PerriŽns JH, St. Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. N Engl J Med 1995;332:779-784.

Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998;157:1881-1884.

Rubel AJ, Garro LC. Social and cultural factors in the successful control of tuberculosis. Public Health Rep 1992;107:626-636.

Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991;324:289-294.

Snider DE. Pregnancy and tuberculosis. Chest 1984;86S:10S-13S.

Snider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61:191-196.

Stead WW, Dutt AK. Tuberculosis in elderly persons. Annu Rev Med 1991;42:267-276.

Sumartojo E. When tuberculosis treatment fails: a social behavioral account of patient adherence. Am Rev Respir Dis 1993;147:1311-1320.

Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995;151:129-135.

Veldkamp AI, Hoetelmans MW, Beijnen JH, Mulder JW, Meenhorst PL. Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999;29:1586.

Villarino ME, Geiter LJ, Simone PM. The multidrug-resistant tuberculosis challenge to public health efforts to control tuberculosis. Public Health Rep 1992:107(6):616-625.

 


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination - http://www.cdc.gov/tb

Please send comments/suggestions/requests to: hsttbwebteam@cdc.gov, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333